-
Je něco špatně v tomto záznamu ?
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies
M. Santoni, J. Molina-Cerrillo, ZW. Myint, F. Massari, T. Buchler, S. Buti, MR. Matrana, U. De Giorgi, M. Rizzo, IO. Zabalza, L. Galli, PA. Zucali, G. Aurilio, L. Incorvaia, M. Bassanelli, G. Mammone, A. Salfi, L. Isella, V. Mollica, E. Grande,...
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 2006-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2006-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 2006-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2006-01-01 do Před 1 rokem
Family Health Database (ProQuest)
od 2006-01-01 do Před 1 rokem
- MeSH
- inhibitory angiogeneze terapeutické užití MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- inhibitory protonové pumpy farmakologie terapeutické užití MeSH
- karcinom z renálních buněk * patologie MeSH
- lidé MeSH
- metformin * farmakologie terapeutické užití MeSH
- nádory ledvin * patologie MeSH
- retrospektivní studie MeSH
- statiny * farmakologie terapeutické užití MeSH
- vaskulární endoteliální růstový faktor A MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Drug-drug interactions are a major concern in oncology and may potentially affect the outcome of patients with cancer. OBJECTIVE: In this study, we aimed to determine whether the concomitant use of statins, metformin, or proton pump inhibitors affects survival in patients with metastatic renal cell carcinoma treated with first-line combination therapies. METHODS: Medical records of patients with documented metastatic renal cell carcinoma between January 2016 and November 2021 were reviewed at 17 participating centers. This research was conducted in ten institutions, including both referral centers and local hospitals. Patients were assessed for overall survival, progression-free survival, and overall clinical benefit. Univariate and multivariate analyses were conducted to explore the association of variables of interest with overall survival and progression-free survival. RESULTS: A total of 304 patients receiving dual immunotherapy (51%) or immunotherapy/vascular endothelial growth factor-tyrosine kinase inhibitor (49%) combinations were eligible for inclusion in this retrospective study. Statin use was a significant prognostic factor for longer overall survival in a univariate analysis (hazard ratio 0.48, 95% confidence interval 0.26-0.87; p = 0.016) and a multivariate analysis (hazard ratio 0.48, 95% confidence interval 0.31-0.74; p < 0.001) and was significantly associated with an overall clinical benefit (83% in statin users vs 71% in non-users; p = 0.045). Otherwise, the use of metformin or proton pump inhibitors did not affect the outcome of these patients. CONCLUSIONS: Our study suggests a prognostic impact of statin use in patients receiving first-line immuno-oncology combinations. The mechanism of this interaction warrants further elucidation.
Department of Biomedical Sciences Humanitas University Pieve Emanuele Milan Italy
Department of Experimental Diagnostic and Specialty Medicine University of Bologna Bologna Italy
Department of Internal Medicine Hematology Oncology Ochsner Medical Center New Orleans LA USA
Department of Medical Oncology Hospital Ramón y Cajal Madrid Spain
Department of Medical Oncology MD Anderson Cancer Center Madrid Madrid Spain
Division of Medical Oncology A O U Consorziale Policlinico di Bari Bari Italy
Markey Cancer Center University of Kentucky Lexington KY USA
Medical Oncology IRCCS Azienda Ospedaliero Universitaria di Bologna Via Albertoni 15 Bologna Italy
Medical Oncology Unit University Hospital of Parma Parma Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22024685
- 003
- CZ-PrNML
- 005
- 20221031100319.0
- 007
- ta
- 008
- 221017s2022 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11523-022-00907-9 $2 doi
- 035 __
- $a (PubMed)35947324
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Santoni, Matteo $u Oncology Unit, Macerata Hospital, Macerata, Italy
- 245 10
- $a Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies / $c M. Santoni, J. Molina-Cerrillo, ZW. Myint, F. Massari, T. Buchler, S. Buti, MR. Matrana, U. De Giorgi, M. Rizzo, IO. Zabalza, L. Galli, PA. Zucali, G. Aurilio, L. Incorvaia, M. Bassanelli, G. Mammone, A. Salfi, L. Isella, V. Mollica, E. Grande, C. Porta, N. Battelli
- 520 9_
- $a BACKGROUND: Drug-drug interactions are a major concern in oncology and may potentially affect the outcome of patients with cancer. OBJECTIVE: In this study, we aimed to determine whether the concomitant use of statins, metformin, or proton pump inhibitors affects survival in patients with metastatic renal cell carcinoma treated with first-line combination therapies. METHODS: Medical records of patients with documented metastatic renal cell carcinoma between January 2016 and November 2021 were reviewed at 17 participating centers. This research was conducted in ten institutions, including both referral centers and local hospitals. Patients were assessed for overall survival, progression-free survival, and overall clinical benefit. Univariate and multivariate analyses were conducted to explore the association of variables of interest with overall survival and progression-free survival. RESULTS: A total of 304 patients receiving dual immunotherapy (51%) or immunotherapy/vascular endothelial growth factor-tyrosine kinase inhibitor (49%) combinations were eligible for inclusion in this retrospective study. Statin use was a significant prognostic factor for longer overall survival in a univariate analysis (hazard ratio 0.48, 95% confidence interval 0.26-0.87; p = 0.016) and a multivariate analysis (hazard ratio 0.48, 95% confidence interval 0.31-0.74; p < 0.001) and was significantly associated with an overall clinical benefit (83% in statin users vs 71% in non-users; p = 0.045). Otherwise, the use of metformin or proton pump inhibitors did not affect the outcome of these patients. CONCLUSIONS: Our study suggests a prognostic impact of statin use in patients receiving first-line immuno-oncology combinations. The mechanism of this interaction warrants further elucidation.
- 650 _2
- $a inhibitory angiogeneze $x terapeutické užití $7 D020533
- 650 12
- $a karcinom z renálních buněk $x patologie $7 D002292
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a statiny $x farmakologie $x terapeutické užití $7 D019161
- 650 12
- $a nádory ledvin $x patologie $7 D007680
- 650 12
- $a metformin $x farmakologie $x terapeutické užití $7 D008687
- 650 _2
- $a inhibitory proteinkinas $x terapeutické užití $7 D047428
- 650 _2
- $a inhibitory protonové pumpy $x farmakologie $x terapeutické užití $7 D054328
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a vaskulární endoteliální růstový faktor A $7 D042461
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Molina-Cerrillo, Javier $u Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain
- 700 1_
- $a Myint, Zin W $u Markey Cancer Center, University of Kentucky, Lexington, KY, USA
- 700 1_
- $a Massari, Francesco $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni-15, Bologna, Italy. francesco.massari@aosp.bo.it $u Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy. francesco.massari@aosp.bo.it $1 https://orcid.org/0000000164766871
- 700 1_
- $a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
- 700 1_
- $a Buti, Sebastiano $u Medical Oncology Unit, University Hospital of Parma, Parma, Italy
- 700 1_
- $a Matrana, Marc R $u Department of Internal Medicine, Hematology/Oncology, Ochsner Medical Center, New Orleans, LA, USA
- 700 1_
- $a De Giorgi, Ugo $u Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
- 700 1_
- $a Rizzo, Mimma $u Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy
- 700 1_
- $a Zabalza, Ignacio Ortego $u Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain
- 700 1_
- $a Galli, Luca $u Oncology Unit 2, University Hospital of Pisa, Pisa, Italy
- 700 1_
- $a Zucali, Paolo Andrea $u Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
- 700 1_
- $a Aurilio, Gaetano $u Medical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology IRCCS, Milan, Italy
- 700 1_
- $a Incorvaia, Lorena $u Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
- 700 1_
- $a Bassanelli, Maria $u Department of Medical and Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy
- 700 1_
- $a Mammone, Giulia $u Department of Radiological, Oncological and Anatomo-Pathological Science, "Sapienza" University of Rome, Rome, Italy
- 700 1_
- $a Salfi, Alessia $u Oncology Unit 2, University Hospital of Pisa, Pisa, Italy
- 700 1_
- $a Isella, Luca $u Medical Oncology Unit, University Hospital of Parma, Parma, Italy
- 700 1_
- $a Mollica, Veronica $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni-15, Bologna, Italy $u Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
- 700 1_
- $a Grande, Enrique $u Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain
- 700 1_
- $a Porta, Camillo $u Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy $u Chair of Oncology, Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy
- 700 1_
- $a Battelli, Nicola $u Oncology Unit, Macerata Hospital, Macerata, Italy
- 773 0_
- $w MED00189571 $t Targeted oncology $x 1776-260X $g Roč. 17, č. 5 (2022), s. 571-581
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35947324 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100317 $b ABA008
- 999 __
- $a ok $b bmc $g 1854428 $s 1175975
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 17 $c 5 $d 571-581 $e 20220810 $i 1776-260X $m Targeted oncology $n Target Oncol $x MED00189571
- LZP __
- $a Pubmed-20221017
